ClinicalTrials.gg
CompletedNCT05392842Updated Oct 24, 2022

Corchorus Olitorius Buccal Films for the Treatment of Recurrent Minor Aphthous Ulcerations

A Phase 1 interventional study of Corchorus Olitorius Buccal fast dissolving Films and plain mucoadhesive fast dissolving film in Aphthous Ulcer Recurrent, sponsored by Deraya University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-24.

Sponsored by Deraya University · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

A methanol extract of Corchorus olitorius edible plant was perpared for extration of glycosideal compounds. the extract was tested for its efficacy as antiinflammatory and analgesic activity invitro and approved by the biomarkers. a fast dissolvinf mucoadhesive film was prepared by a certain amounts of highly safe polymers for a pilote study on human for treament of Aphthous Ulcerations. two groups of study, placebo and intrvention will be recurited and followed for pain, erthymia and size of ulcers for 6 days.

02

Conditions studied

  • Aphthous Ulcer Recurrent

Browse trials for

03

In context

Stomatitis, Aphthous

63 studies on the registry are indexed under Stomatitis, Aphthous; 17 are open to participants now.

This study's enrollment of 20 is below the median of 41 across 54 interventional studies indexed under Stomatitis, Aphthous.

Browse Stomatitis, Aphthous studies →

Lead sponsor

Deraya University is the lead sponsor of 50 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females aged 18-65 years old
  2. Willingness to participate and sign the forms
  3. Presenting with 1 to 5 aphthous ulcers (less than 72 hours' duration) with a size no greater than 5 mm in diameter
  4. An expectation that their ulcers normally take 5 or more days to resolve without treatment

Exclusion criteria

Exclusion Criteria:

  • A known history of serious drug 2. Pregnancy and lactation (Urine hCG-positive) 3. Concurrent clinical conditions that could pose a health risk to the subjects, including serious liver, kidney, and heart dysfunctions 4. A history of an immunologic problem
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Placebo comparator
    Placebo group

    plain mucoadhesive fast dissolving film

    Dietary Supplement: plain mucoadhesive fast dissolving film

  • Experimental
    Treated group

    Corchorus Olitorius Buccal Films

    Dietary Supplement: Corchorus Olitorius Buccal fast dissolving Films

Interventions

  • Dietary supplementCorchorus Olitorius Buccal fast dissolving Films

    Corchorus Olitorius Buccal fast dissolving Films

  • Dietary supplementplain mucoadhesive fast dissolving film

    plain mucoadhesive fast dissolving film

06

What researchers measure

Primary outcomes

  1. treatment of ulcer

    ulcer size by the investigator, the diameter measured as the distance between two oppisit points of the wight area of ulcer

    Time frame: 6 days

Secondary outcomes

  1. Pain scoring

    pain measured by VAS tool, 0 the least pain while 10 the highest one

    Time frame: 6 days

  2. Erthymia

    Erthymia estimated by the dgree of redness by the investgator, the darkest indicadetes the worst one

    Time frame: 6 days

07

Study locations

1 site
  • Minya university, faculty of medicin
    Minya, المنيا 05673, Egypt
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05392842
Lead sponsor
Deraya University
Responsible party
Soad Ali (Clinical professor, Deraya University) — Principal investigator
First posted
May 26, 2022
Start date
Apr 10, 2022
Primary completion
Jun 18, 2022
Completion
Jul 1, 2022
Last update
Oct 24, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion